Literature DB >> 21148721

A central role for CD68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion.

Thenappan Thenappan1, Ankush Goel, Glenn Marsboom, Yong-Hu Fang, Peter T Toth, Hannah J Zhang, Hidemi Kajimoto, Zhigang Hong, Jonathan Paul, Christian Wietholt, Jennifer Pogoriler, Lin Piao, Jalees Rehman, Stephen L Archer.   

Abstract

RATIONALE: The etiology of hepatopulmonary syndrome (HPS), a common complication of cirrhosis, is unknown. Inflammation and macrophage accumulation occur in HPS; however, their importance is unclear. Common bile duct ligation (CBDL) creates an accepted model of HPS, allowing us to investigate the cause of HPS.
OBJECTIVES: We hypothesized that macrophages are central to HPS and investigated the therapeutic potential of macrophage depletion.
METHODS: Hemodynamics, alveolar-arterial gradient, vascular reactivity, and histology were assessed in CBDL versus sham rats (n = 21 per group). The effects of plasma on smooth muscle cell proliferation and endothelial tube formation were measured. Macrophage depletion was used to prevent (gadolinium) or regress (clodronate) HPS. CD68(+) macrophages and capillary density were measured in the lungs of patients with cirrhosis versus control patients (n = 10 per group).
MEASUREMENTS AND MAIN RESULTS: CBDL increased cardiac output and alveolar-arterial gradient by causing capillary dilatation and arteriovenous malformations. Activated CD68(+)macrophages (nuclear factor-κB+) accumulated in HPS pulmonary arteries, drawn by elevated levels of plasma endotoxin and lung monocyte chemoattractant protein-1. These macrophages expressed inducible nitric oxide synthase, vascular endothelial growth factor, and platelet-derived growth factor. HPS plasma increased endothelial tube formation and pulmonary artery smooth muscle cell proliferation. Macrophage depletion prevented and reversed the histological and hemodynamic features of HPS. CBDL lungs demonstrated increased medial thickness and obstruction of small pulmonary arteries. Nitric oxide synthase inhibition unmasked exaggerated pulmonary vasoconstrictor responses in HPS. Patients with cirrhosis had increased pulmonary intravascular macrophage accumulation and capillary density.
CONCLUSIONS: HPS results from intravascular accumulation of CD68(+)macrophages. An occult proliferative vasculopathy may explain the occasional transition to portopulmonary hypertension. Macrophage depletion may have therapeutic potential in HPS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21148721      PMCID: PMC3086745          DOI: 10.1164/rccm.201008-1303OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  47 in total

Review 1.  Pulmonary-Hepatic vascular Disorders (PHD).

Authors:  R Rodríguez-Roisin; M J Krowka; Ph Hervé; M B Fallon
Journal:  Eur Respir J       Date:  2004-11       Impact factor: 16.671

2.  Imatinib (Gleevec)-induced hepatotoxicity.

Authors:  Walid S Ayoub; Stephen A Geller; Tram Tran; Paul Martin; John M Vierling; F Fred Poordad
Journal:  J Clin Gastroenterol       Date:  2005-01       Impact factor: 3.062

3.  Smooth muscle cell migration and proliferation are mediated by distinct phases of activation of the intracellular messenger mitogen-activated protein kinase.

Authors:  P R Nelson; S Yamamura; L Mureebe; H Itoh; K C Kent
Journal:  J Vasc Surg       Date:  1998-01       Impact factor: 4.268

4.  Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product.

Authors:  K Hoshino; O Takeuchi; T Kawai; H Sanjo; T Ogawa; Y Takeda; K Takeda; S Akira
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

5.  Common bile duct ligation in the rat: a model of intrapulmonary vasodilatation and hepatopulmonary syndrome.

Authors:  M B Fallon; G A Abrams; J W McGrath; Z Hou; B Luo
Journal:  Am J Physiol       Date:  1997-04

6.  Role of macrophages in acetaminophen (paracetamol)-induced hepatotoxicity.

Authors:  R D Goldin; I D Ratnayaka; C S Breach; I N Brown; S N Wickramasinghe
Journal:  J Pathol       Date:  1996-08       Impact factor: 7.996

Review 7.  Pulmonary intravascular phagocytosis in liver disease.

Authors:  S W Chang; N Ohara
Journal:  Clin Chest Med       Date:  1996-03       Impact factor: 2.878

8.  Hypoxic pulmonary hypertension is prevented in rats with common bile duct ligation.

Authors:  Masatoshi Imamura; Bao Luo; Jennifer Limbird; Andrea Vitello; Masahiko Oka; D Dunbar Ivy; Ivan F McMurtry; Chrystelle V Garat; Michael B Fallon; Ethan P Carter
Journal:  J Appl Physiol (1985)       Date:  2004-10-29

9.  VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling.

Authors:  K Gupta; S Kshirsagar; W Li; L Gui; S Ramakrishnan; P Gupta; P Y Law; R P Hebbel
Journal:  Exp Cell Res       Date:  1999-03-15       Impact factor: 3.905

10.  Chronic biliary obstruction induces pulmonary intravascular phagocytosis and endotoxin sensitivity in rats.

Authors:  S W Chang; N Ohara
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

View more
  57 in total

Review 1.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.

Authors:  Wenli Yang; Junlan Zhang; Bingqian Hu; Wei Wu; Julie Venter; Gianfranco Alpini; Michael B Fallon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-07       Impact factor: 4.052

Review 3.  Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.

Authors:  Gaetano Bertino; Graziella Privitera; Francesco Purrello; Shirin Demma; Emanuele Crisafulli; Luisa Spadaro; Nikolaos Koukias; Emmanuel A Tsochatzis
Journal:  Intern Emerg Med       Date:  2016-06-07       Impact factor: 3.397

Review 4.  Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch; Christophe Guignabert; Marc Humbert; Mark R Nicolls
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

5.  Pulmonary hypertension begets pulmonary hypertension: mutually reinforcing roles for haemodynamics, inflammation, and cancer-like phenotypes.

Authors:  Danchen Wu; Stephen L Archer
Journal:  Cardiovasc Res       Date:  2016-05-23       Impact factor: 10.787

6.  Myeloid-derived Suppressor Cells Are Necessary for Development of Pulmonary Hypertension.

Authors:  Andrew J Bryant; Vinayak Shenoy; Chunhua Fu; George Marek; Kyle J Lorentsen; Erica L Herzog; Mark L Brantly; Dorina Avram; Edward W Scott
Journal:  Am J Respir Cell Mol Biol       Date:  2018-02       Impact factor: 6.914

Review 7.  Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.

Authors:  Sarah Raevens; Michael B Fallon
Journal:  Hepatology       Date:  2018-11       Impact factor: 17.425

8.  CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension.

Authors:  Yen-Rei A Yu; Lan Mao; Claude A Piantadosi; Michael D Gunn
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

Review 9.  Pulmonary complications of hepatic diseases.

Authors:  Salim R Surani; Yamely Mendez; Humayun Anjum; Joseph Varon
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 10.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.